Pumpkin seed Cucurbita pepo L.
Also called: pumpkin seed oil, Cucurbitae semen
Pumpkin seed is the whole, ripe, dried seed of Cucurbita pepo, a crop plant that originated as a cultigen in Mexico. The seeds are about 50% fatty oil. An EU traditional-use monograph covers the seeds, extracts and oil for lower urinary tract symptoms.
- Category
- Botanical
- Part used
- Whole, ripe, dried seed; soft and dry extracts; fatty oil
- Strongest evidence
- C Limited
- Native range
- Native to Mexico as a cultigen (POWO: "as a cultigen from Mexico")
- Reviewed
- 2026-10-29
Class 3 Limited studies in people. No review stating a count was found. This entry cites 2 RCTs of pumpkin seed alone: GRANU (1,431 men; seed and seed-extract arms) and seed oil versus tamsulosin (73 men). The hair-loss trial's branded product is not counted; its full composition was not confirmed. [2]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CHormones and reproduction2 topics
CKidneys and bladder1 topic
CSkin and hair1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Urinary symptoms from benign prostatic enlargement | C | In a 12-month, partially blinded RCT of 1,431 men aged 50–80, response with pumpkin seed (5 g twice daily) was 58.5% versus 47.3% with placebo (descriptively significant); seed-extract capsules did not differ from placebo. [2] |
| Prostate symptoms: seed oil versus tamsulosin | C | In a 3-month single-blind trial of 73 men, symptom scores improved with pumpkin seed oil (360 mg twice daily) and with tamsulosin, but fell more with tamsulosin by months 1 and 3. [3] |
| Overactive bladder in women (combination product) | C | An uncontrolled, industry-funded 12-week observational study of a pumpkin seed oil, Rhus aromatica and hop combination in 117 women reported fewer daytime and nighttime urinations. [4] |
| Male pattern hair loss | C | In a 24-week double-blind RCT in 76 men, 400 mg/day of a pumpkin seed oil product increased hair counts by 40% versus 10% with placebo. [5] |
Main constituents: About 50% fatty oil (mostly linoleic and oleic acids, with tocopherol); putative active constituents are Δ7-sterols (avenasterol, spinasterol) and Δ5-sterols (sitosterol, stigmasterol) [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Studied in trials: pumpkin seed 5 g twice daily or seed-extract capsules 500 mg twice daily for 12 months. [2]
- Studied in trials: pumpkin seed oil 360 mg twice daily for 3 months. [3]
- Studied in trials: 400 mg/day of pumpkin seed oil for 24 weeks. [5]
- Stated in a regulatory monograph (EU, EMA HMPC, 2012), traditional use: seed 2.5–7.5 g twice daily; fatty oil 1–1.2 g 3 times daily (3–4 g/day); long-term use is possible. [6]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingEU monograph (2012): safety in pregnancy and lactation has not been established for pumpkin extracts and use is not recommended …
1 statement in the profile.
Details and sources - Interactions with medicinesNone reported
Medicines in general: EU monograph (EMA HMPC, 2012), section 4.5: none reported.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked. The profile notes other test results.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
EU (EMA HMPC monograph, 20 November 2012), traditional use, adults and elderly: seed or comminuted seed 2.5–7.5 g twice daily …
Details and sources
- Mild gastrointestinal complaints have been reported; the frequency is common (4%) (EU monograph). [6]
- The EU monograph does not recommend use under 18 years, because lower urinary tract symptoms in this group require medical supervision. Pumpkin extracts are not recommended in pregnancy and lactation; seeds and fatty oil can be used then if clinically needed. [6]
- See a doctor if fever, spasms, blood in the urine, painful urination or urinary retention occur (EU monograph). [6]
- In the 12-month GRANU trial, the study products were well tolerated. [2]
Identity, quality and standardization
- There is no European Pharmacopoeia monograph; the German Pharmacopoeia defines the substance as whole, dry, ripe seeds of Cucurbita pepo and/or other cultivated varieties. [1]
Regulatory status
- US: No NDI notification naming pumpkin seed (Cucurbita pepo) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [7]
- EU: EMA's HMPC monograph (2012) recognizes traditional use for lower urinary tract symptoms related to benign prostatic hyperplasia or overactive bladder, after serious conditions have been excluded by a doctor. [6]
- US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed, and that it generally does not approve supplement claims or other labeling before use. [8]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming pumpkin seed (Cucurbita pepo) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of pumpkin seed (Cucurbita pepo) was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P3]
- NTP technical reports list checked: no report on pumpkin seed or Cucurbita. [P4]
- EU monograph: tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed. [P5]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Medicines in general: EU monograph (EMA HMPC, 2012), section 4.5: none reported. [P5]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test of each dietary-ingredient lot (at least one appropriate test or examination) — Required for any component that is a dietary ingredient under 21 CFR 111.75(a)(1)(i), unless FDA grants a petition exemption. [P6]
- Identity against the German Pharmacopoeia definition (whole, dry, ripe seeds of Cucurbita pepo and/or cultivated varieties) — No European Pharmacopoeia monograph exists; the EU monograph refers to the German monograph (DAB 10, 1999). [P1]
Supply and conservation
- IUCN Red List: Least Concern (LC), via GBIF species API, retrieved 2026-10-29. [P7]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- EU (EMA HMPC monograph, 20 November 2012), traditional use, adults and elderly: seed or comminuted seed 2.5–7.5 g twice daily; soft extract 500 mg twice daily; dry extract 105 mg 3 times daily or 152 mg twice daily; fatty oil 1–1.2 g 3 times daily (3–4 g/day). [P5]
Pregnancy and breastfeeding
- EU monograph (2012): safety in pregnancy and lactation has not been established for pumpkin extracts and use is not recommended; no concern about malformations has arisen after consumption of pumpkin seeds and fatty oil, which can be used in pregnancy and lactation if clinically needed. [P5]
Sources for this profile
- European Medicines Agency (HMPC). Assessment report on Cucurbita pepo L., semen. EMA/HMPC/136022/2010 (20 November 2012), 2012-11-20. ema.europa.eu
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. Agents Classified by the IARC Monographs, Volumes 1–142 (list last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (list of 2-year studies; checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- European Medicines Agency (HMPC). Community herbal monograph on Cucurbita pepo L., semen. EMA/HMPC/136024/2010 (20 November 2012), 2012-11-20. ema.europa.eu
- eCFR. 21 CFR 111.75 What must you do to determine whether specifications are met? (text retrieved through the eCFR versioner API, version of 2026-09-01), 2026-09-01. ecfr.gov
- GBIF species API: IUCN Red List category for Cucurbita pepo, 2026-10-29. api.gbif.org
Sources
- European Medicines Agency (HMPC). Assessment report on Cucurbita pepo L., semen. EMA/HMPC/136022/2010 (20 November 2012), 2012-11-20. ema.europa.eu
- Vahlensieck W, et al. Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study. Urol Int 2015;94(3):286-95 (PMID 25196580), 2015. pubmed.ncbi.nlm.nih.gov
- Zerafatjou N, et al. Pumpkin seed oil (Cucurbita pepo) versus tamsulosin for benign prostatic hyperplasia symptom relief: a single-blind randomized clinical trial. BMC Urol 2021;21(1):147 (PMID 34666728), 2021-10-19. pubmed.ncbi.nlm.nih.gov
- Gauruder-Burmester A, et al. Cucurbita pepo-Rhus aromatica-Humulus lupulus combination reduces overactive bladder symptoms in women - a noninterventional study. Planta Med 2019;85(13):1044-1053 (PMID 31261419), 2019-09. pubmed.ncbi.nlm.nih.gov
- Cho YH, et al. Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: a randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med 2014;2014:549721 (PMID 24864154), 2014. pubmed.ncbi.nlm.nih.gov
- European Medicines Agency (HMPC). Community herbal monograph on Cucurbita pepo L., semen. EMA/HMPC/136024/2010 (20 November 2012), 2012-11-20. ema.europa.eu
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Cucurbita pepo L. (accessed 2026-10-29). powo.science.kew.org
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.